BioCorRx Inc. · OTC:BICX
BioCorRx — Investor Presentation (December 2025)
19 slides from BioCorRx's investor presentation, Dec 11, 2025
Slide 1: Corporate Presentation
Corporate Presentation December 11, 2025 BioCorRx® Inc. - OTCQB:BICX
Slide 2: Safe Harbor Statement
Safe Harbor Statement ⎼ This presentation is not intended to be promotional but is intended for confidential investor and potential investor overview information only. In addition to historical facts or statements of current condition, this presentation, may contain forward- looking statements. Forw
Slide 3: Executive Summary
Executive Summary Unmet need Technology Milestones There is no long-acting BICX104 is an implantable, BICX104 is following a treatment (>30 days) on the long-acting naltrexone 505(b)(2) registration US market for patients with pellet in development for pathway with potential for OUD, AUD or MUD1. th
Slide 4: BioCorRx is a Leader in Addiction Treatment
BioCorRx® is a Leader in Addiction Treatment Holding Company Holding Company Conquering challenges Our Majority Owned Subsidiary Innovating with purpose Helping families For over a decade, BioCorRx® has been developing a comprehensive approach to treatment programs for Improving lives substance use
Slide 5: Humanity is drowning in a global addiction crisis
Humanity is drowning in a global addiction crisis 16M opioid use disorder (OUD) 100M alcohol use disorder (AUD) 27M methamphetamine use disorder (MUD) 1B obesity 108,000 ~$1.5T people died from drug-involved overdose was the estimated US economic burden of from illicit or prescription drugs in the U
Slide 6: Naltrexone is an important medication in the treatment of Substance Use Disorder
Naltrexone is an important medication in the treatment of Substance Use Disorder (SUD) Long track record of Attenuates Non-narcotic Effective in No safety & cravings for & harm withdrawal efficacy (FDA opioids & non-addictive reduction symptoms approved alcohol when ceasing since 1984) use BioCorRx
Slide 7: The first three months of treatment come with a high risk of relapse
The first three months of treatment come with a high risk of relapse 70% Up to 91% of AUD patients relapse within 12 months, of OUD patients will relapse3 with the first 3 months being high risk1,2 BICX104 is a sustained, three-month treatment that potentially offers an option for patients suffering
Slide 8: BICX104 – 3 months of naltrexone in one implant
BICX104 – 3 months of naltrexone in one implant 100% 15 min biodegradable in-office procedure Removable Solution if needed For non-compliance 8
Slide 9: BioCorRx Pharmaceuticals pipeline
BioCorRx Pharmaceuticals pipeline Program Pre-Clinical Phase 1 Phase 2 BICX104 for Opioid Use Disorder1 BICX104 for Alcohol Use Disorder1 BICX104 for Methamphetamine Use Disorder1 BICX104 for Food Addiction/Weight Loss* 1 National Institute on Drug Abuse ; 2 Patent Granted 2023; * https://www.youtub
Slide 10: Study 21-01a: Phase 1 Trial at a Glance
Study 21-01a: Phase 1 Trial at a Glance (NCT04828694) ⎼ Study Design & Registry Details • Study: Pharmacokinetic and Safety Study of naltrexone release from subcutaneous BICX104 pellets vs Vivitrol® • Design: Phase 1, randomized, open-label, parallel-group, interventional study in healthy volunteers
Slide 11: Study 21-01a: Pharmacokinetics & Safety (12-week implant)
Study 21-01a: Phase 1 Pharmacokinetics & Safety (12-week implant) ⎼ Long-acting subcutaneous implant designed for ~3-month naltrexone delivery. • First-in-human PK/safety study compared implant to a marketed IM naltrexone injection (Vivitrol®) in healthy volunteers. • PK: sustained exposure over 12
Slide 12: BICX104: Development Strategy Overview
BICX104: Development Strategy Overview ⎼ Target indications under evaluation: OUD, AUD, and MUD. • Regulatory approach: 505(b)(2) pathway leveraging prior naltrexone experience. • Program plan (high level): IND submission → 1–2 clinical efficacy studies in MUD → NDA submission. • Potential value: 3-
Slide 13: Medical, scientific, and regulatory consultants
Medical, scientific, and regulatory consultants Kate Beebe DeVarney, Ph.D. Dr. DeVarney the principal investigator Joseph DeSanto, M.D. is a Board-Certified physician who practices Addiction Priya Jambehekar, M.Sc. in Organic & Biochemistry and M.S. in for the BICX104 programs and Director of BioCorR
Slide 14: Commercial leadership consultants
Commercial leadership consultants Will Clodfelter, MBA, Will G. Clodfelter is a biotech and medical device executive (CEO/CBO) with deep experience in corporate development, strategy, and monetizing programs from startup through large pharma. He’s recognized for translating complex science and engin
Slide 15: Medication Assisted Treatment Program
Medication Assisted Treatment Program MAT programs may utilize naltrexone, or other medications such as buprenorphine and methadone. Proprietary Cognitive Behavioral Therapy (CBT) Program • Beat Addiction Recovery offers CBT through its proprietary 35 module curriculum that can be used by the patien
Slide 16: Medication Assisted Weight Loss Program
Medication Assisted Weight Loss Program 3-Month Program Medically Assisted Weight Loss - Intake - Enrollment Virtual Lifestyle Group Support - Engagement - Retention Virtual Health and Wellness Support Groups Medical On-Demand Virtual Support Behavioral Group Support ⎼ Medical Evaluation and Assessm
Slide 17: LUCEMYRA is the only FDA-approved, non-opioid treatment for opioid withdrawal
LUCEMYRA® is the only FDA-approved, non-opioid, non-addictive treatment for relief of multiple symptoms of opioid withdrawal that may happen when you stop taking an opioid suddenly1What is LUCEMYRA?LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid with
Slide 18: Important Safety Information
Important Safety Information(1) LUCEMYRA should be used with caution with any medications that decrease pulse or blood pressure to avoid the risk of excessive bradycardia and hypotension. Patients using LUCEMYRA should be monitored for symptoms related to bradycardia and orthostasis. LUCEMYRA prolon
Slide 19: A leadership team with decades of industry experience
A leadership team with decades of industry experience Lourdes Felix Lourdes Felix CEO, CFO & Director Founder & President Kate Beebe DeVarney, Ph.D. Lou Lucido Principal Investigator and President & Director Director for BioCorRx Pharmaceuticals Inc. Scott Henley, MBA Director of Clinical Project Ma